/

Batteries & E-Mobility

/

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

Verified Nov 2026

Batteries & E-Mobility

·

United States flag

Newton, Massachusetts

·

Since 2008

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, founded in 2008. With 200–500 employees and estimated revenue of $100–250 million, the company develops oncology therapies targeting nuclear export dysregulation. Its lead product, XPOVIO® (selinexor), is an oral XPO1 inhibitor approved in the U.S. for blood cancers and solid tumors, with pipeline candidates including eltanexor and compounds for myelofibrosis.

Karyopharm Therapeutics Inc.

Verified Nov 2026

AT A GLANCE

Founded

2008

Headquarters

United States flag

Newton, Massachusetts

Employees

200-500

Ownership

Karyopharm Therapeutics Inc. at a glance

Revenue

$100-250M

Est. band

Employees

200-500

Founded

2008

Headquarters

Newton, Massachusetts

Industries

Automotive

Electric Vehicles

Medical

Overview

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, founded in 2008. With 200–500 employees and estimated revenue of $100–250 million, the company develops oncology therapies targeting nuclear export dysregulation. Its lead product, XPOVIO® (selinexor), is an oral XPO1 inhibitor approved in the U.S. for blood cancers and solid tumors, with pipeline candidates including eltanexor and compounds for myelofibrosis.

At a glance

Attribute

Detail

Founded

2008

Headquarters

Newton, Massachusetts

Employees

200-500

Revenue

$100-250M (estimated)

Primary capability

Batteries & E-Mobility

What Karyopharm Therapeutics Inc. makes

The company employs its proprietary SINE technology platform to develop small-molecule drugs that inhibit Exportin 1 (XPO1), a protein essential for cell transport, addressing high-unmet-need cancer indications.

Latest developments

Company details

As a private, commercial-stage biotech firm, Karyopharm serves the oncology and medical sectors with clinical-stage advancement toward regulatory submissions, including a Phase 3 trial readout for myelofibrosis. Karyopharm Therapeutics Inc. was founded in 2008, has an estimated 200-500 employees, and is headquartered in Newton, Massachusetts.

Frequently asked questions

What does Karyopharm Therapeutics Inc. make?

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, founded in 2008. With 200–500 employees and estimated revenue of $100–250 million, the company develops oncology therapies targeting nuclear export dysregulation. Its lead product, XPOVIO® (selinexor), is an oral XPO1 inhibitor approved in the U.S. for blood cancers and solid tumors, with pipeline candidates including eltanexor and compounds for myelofibrosis.

Where is Karyopharm Therapeutics Inc. headquartered?

Karyopharm Therapeutics Inc. is headquartered in Newton, Massachusetts (85 Wells Avenue, Newton, Massachusetts, 02459).

When was Karyopharm Therapeutics Inc. founded?

Karyopharm Therapeutics Inc. was founded in 2008.

How big is Karyopharm Therapeutics Inc.?

Karyopharm Therapeutics Inc. has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Newton, Massachusetts (HQ)Headquarters · United States
Newton, Massachusetts (HQ)85 Wells Avenue, Newton, Massachusetts, 02459, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.